Drata Is Becoming Pharma’s Fastest Path to AI Compliance Readiness
What is Drata? Drata is a continuous trust management platform (GRC tools) that automates governance, risk, and compliance workflows for organisations that must prove security and regulatory readiness. The platform continuously monitors technical controls, collects evidence, and maps control status to multiple frameworks (SOC 2, ISO 27001, HIPAA, GDPR, HITRUST, NIST, FedRAMP and others). Drata’s […]
What is Drata?
Drata is a continuous trust management platform (GRC tools) that automates governance, risk, and compliance workflows for organisations that must prove security and regulatory readiness. The platform continuously monitors technical controls, collects evidence, and maps control status to multiple frameworks (SOC 2, ISO 27001, HIPAA, GDPR, HITRUST, NIST, FedRAMP and others). Drata’s no-code configuration and automated evidence collection reduce manual work, speed audit preparation, and provide real-time dashboards for risk and control posture. Used by startups through enterprise teams, Drata streamlines vendor security reviews, shortens compliance timelines, and centralises documentation to support secure customer onboarding and faster sales cycles.
Why Leading Healthcare Teams Trust Drata
- Over 7,500 organisations globally use Drata, including OpenAI, VIVIO Health, LinkedIn and Asana
- AWS Security Competency Partner with an AI engine built on AWS Bedrock
- Named #1 highest rated cloud compliance software on G2 for customer satisfaction
- Trust Centre feature enables organisations to display real-time control status, security reports, certifications, and policies to reduce security review friction
- Supports 20+ pre-built compliance frameworks with customizable options for organisations with unique requirements
- Integrates with 45+ AWS services and streamlines over 20 compliance frameworks, including HIPAA, PCI DSS, and GDPR
- Automates evidence collection and control monitoring to accelerate audit readiness and reduce time spent preparing for audits
- Implements tenant-specific machine learning models, generative AI content guardrails, and data anonymisation to protect customer data
- Follows strict access control and encryption protocols aligned to global data regulations with data masking strategies
- Ensures GDPR compliance as a top organisational priority for handling customer data
- Achieved $1 billion valuation in November 2021 with $100 million Series B funding, making it one of the fastest SaaS companies to reach unicorn status
- Raised $200 million in Series C funding in December 2022, doubling valuation to $2 billion
- Total funding of $328 million raised across four rounds, with a current $2 billion valuation
- Acquired SafeBase in February 2025 for $250 million to expand trust centre and security review capabilities
- Acquired Harmonise in April 2024 for employee access management and oak9 in May 2024 for developer security to build a full-stack GRC platform
- Strategic acquisitions position Drata as a comprehensive Trust Management platform integrating trust centres, developer security, and access governance
-
Watch Overview
Top 3 Pain Points Drata Fixes in Healthcare
| Problem | How Drata Solves It |
|---|---|
| 1. Slow, manual compliance processes | Drata automates evidence collection, policy management, and continuous control monitoring, reducing audit prep time from weeks to hours. |
| 2. Lack of real-time visibility into AI and cloud risks | Continuous monitoring surfaces issues instantly, giving teams a live compliance dashboard across systems, vendors, and AI workloads. |
| 3. Difficulty scaling AI governance across teams and regions | Drata standardises controls, automates workflows, and supports multiple frameworks, helping organisations scale GxP, model governance, and security compliance globally. |
Feature Category Summary: Drata
| Feature Category | Summary | Association (YES, NO, NA) |
|---|---|---|
| Regulatory-Ready | Drata is a security and compliance automation GRC platform that continuously monitors security and compliance controls, automatically collects audit evidence, and maps controls across more than 20 frameworks including SOC 2, ISO 27001, HIPAA, GDPR, PCI DSS, NIST 800-53, and HITRUST, with live dashboards, user access reviews, vendor risk management, and AI-powered control suggestions for policy mapping that help organizations maintain audit readiness and satisfy external auditors; however, it does not provide domain-specific FDA/EMA or GxP validation templates out of the box. | YES |
| Clinical Trial Support | Drata is positioned as industry-agnostic GRC and security-compliance automation focused on information security and privacy (SOC 2, ISO, HIPAA, HITRUST, PCI, GDPR), and available materials and marketplaces do not describe capabilities for clinical trial protocol design, site/patient recruitment, safety monitoring, or trial reporting; any life-sciences usage is for security and compliance rather than CTMS-like workflows. | NO |
| Supply Chain & Quality | The platform automates risk assessments and vendor due diligence, providing centralized vendor risk management and continuous monitoring of third-party controls, but it does not manage manufacturing quality, GMP batch release, or counterfeit detection; its supply-chain relevance is limited to assessing security/compliance posture of vendors rather than operational QA. | NO |
| Efficiency & Cost-Saving | Drata emphasizes reducing audit preparation time and manual evidence collection through deep integrations with 180+ tools, continuous control monitoring, automated evidence gathering, and real-time audit-readiness dashboards, with partners reporting markedly faster SOC 2 and ISO 27001 readiness (e.g., SOC 2 Type 1 in 6–8 weeks) and leaner compliance lifecycles, which translates directly into staff time and cost savings. | YES |
| Scalable / Enterprise-Grade | Drata is listed as an AWS Security Competency Partner and GRC solution on AWS Marketplace with integrations to AWS, Azure, GCP, GitHub, Jira, and many SaaS platforms, supports automation for 20+ frameworks, and is marketed to SaaS, fintech, healthtech, and other cloud-native enterprises with fast-moving DevOps pipelines, indicating a multi-tenant, cloud-native architecture suitable for large enterprises though specific large pharma deployments are mentioned only generically (e.g., “pharma AI compliance readiness”). | YES |
| HIPAA Compliant | Drata supports HIPAA and HITRUST frameworks natively, allowing organizations to configure HIPAA/HITRUST control sets, automate evidence collection, and manage risks and vendor compliance against these frameworks, and customer references from healthcare and healthtech organizations use Drata for HIPAA-related security control monitoring, although Drata itself is not a healthcare data system of record but a GRC system processing configuration and log data. | YES |
| Clinically Validated | As a horizontal GRC/compliance automation tool, Drata does not provide clinical decision support or diagnostic algorithms, and there is no evidence of prospective clinical validation trials, medical device clearances, or clinical outcome studies for Drata; its validation concerns security and compliance workflows rather than patient outcomes. | NA |
| EHR Integration | Drata integrates with cloud platforms, code repositories, ticketing systems, HRIS, and other SaaS tools to collect security and compliance evidence, but public documentation does not mention direct integration with EHR systems (e.g., Epic, Cerner) or health-data interoperability standards such as HL7 or FHIR, since its focus is on controls and logs rather than clinical workflow integration. | NO |
| Explainable AI | Drata uses AI to suggest control mappings for new or updated policies and to enhance vendor-risk reviews, with communications emphasizing that customers remain fully in control and can accept or reject AI recommendations, but there is no detailed description of explainable-AI features such as feature-attribution, rationale reports, or transparency dashboards; the emphasis is on workflow assistance rather than model interpretability. | NA |
| Real-Time Analytics | The platform offers continuous, real-time monitoring of security controls, daily automated validation of control performance, real-time alerts on exceptions, and live dashboards on framework progress and system changes impacting compliance, and allows organizations to share their “real-time compliance posture” with customers via a Trust Center, satisfying the requirement for real-time compliance analytics. | YES |
| Bias Detection | Drata focuses on information-security and privacy controls and does not advertise model-level bias detection or fairness analytics across demographic subgroups; even in AI-related materials, the emphasis is on control mapping and evidence collection for AI use rather than algorithmic-bias diagnostics. | NO |
| Ethical Safeguards | Drata enables governance by providing centralized policy management, continuous monitoring of AI and non-AI controls, vendor risk management, and a Trust Center for transparent sharing of certifications and control status, and its leadership discusses the need for human oversight, visibility into AI data lineage, and ongoing validation for AI use; however, there is no concrete product feature set for consent capture, AI use-case whitelisting, or enforced human-in-the-loop decision gating beyond general GRC workflows. | NA |
Risks & Limitations: Drata
-
Continuous monitoring and automated evidence are limited by the coverage and quality of integrated data sources; unsupported or poorly instrumented systems may require manual evidence.
-
Platform outputs are decision-support; human review, governance, and auditor sign-off remain required for formal compliance attestations.
-
Deep integrations with legacy on-prem systems or proprietary medical devices may require engineering effort and professional services.
-
Use in regulated contexts (e.g., validated GMP/CSV environments) requires customers to include the platform in their validation plans and demonstrate appropriate change control and evidence traceability.
